AEON Biopharma (NASDAQ:AEON) & Galera Therapeutics (NASDAQ:GRTX) Critical Comparison

AEON Biopharma (NASDAQ:AEON) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Profitability

This table compares AEON Biopharma and Galera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Galera Therapeutics	N/A	N/A	-99.34%

Insider & Institutional Ownership

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by company insiders. Comparatively, 12.9% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares AEON Biopharma and Galera Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63 million	($5.00)	-0.14
Galera Therapeutics	N/A	N/A	-$59.08 million	$0.64	0.16

AEON Biopharma is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for AEON Biopharma and Galera Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	1	1	1	3.00
Galera Therapeutics	0	0	0	0	0.00

Risk & Volatility

AEON Biopharma has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.64, meaning that its share price is 164% more volatile than the S&P 500.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

About Galera Therapeutics

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.